Blog

Generic sildenafil and tadalafil cost cents a tablet at a wholesale-style pharmacy, which means an ED brand earns nothing on the drug and everything on the service around it. This is the 2026 launch guide: the formulary, what the big brands charge, the intake screens that keep the program safe, and the retention problem that on-demand use creates. ED medications are not controlled substances, so the DEA's December 31 deadline does not touch this category.

Yes, for a narrower set of founders than in 2024. Rock Health counted $11.1 billion of digital health venture funding across 358 deals through Q3 2026 and 164 M&A exits, so money and buyers are both present. Margins are another story: Hims' gross margin fell from 76% to 64% on the branded shift, BetterHelp's cash-pay revenue fell 12%, and CVS sells a $29 weight-loss visit. Here is the evidence, and our view on who should start one now and who should not.

Bask Health and Turbopills sell the same category of product: storefront, intake, providers, pharmacy and billing under your brand. Bask is the bigger and more self-serve of the two, with 250+ companies on it, a free entry point, and $499 and $3,500 monthly tiers in its own July 2026 plan guide. Here is where the two differ (mobile app, API access, payments, onboarding) and who should pick which.

A telehealth refund policy has to answer one question at every stage of the order: has a clinician approved treatment, and has a pharmacy dispensed anything? Before approval there should be nothing to refund; after dispensing, most state pharmacy rules mean the medication cannot come back. This post maps what is refundable at each stage, how cancellation and renewal reminders should work under ROSCA and California's auto-renewal law, how the policy connects to Visa's 1.5% dispute threshold, and ends with policy text you can adapt.

Ten thousand dollars buys a legal telehealth business in one state: the professional corporation, lean counsel, three months of a medical director, first-year insurance, a LegitScript application and a low-cost platform. It does not buy an ad test worth reading, and it does not buy a single line of custom software. Here is the ledger, what to cut and what never to cut, and the one kind of founder for whom $10,000 is enough.

A telehealth business plan that a lender, investor or pharmacy partner will actually read has nine sections, and most of the weight sits in three: the clinical and legal structure, the unit economics, and the month the cash runs lowest. This template gives you each section with what to write in it, then fills it in for a fictional GLP-1 brand using 2026 prices ($349 branded Wegovy cash price, Wegovy pill from $149) and the same assumptions as our margin model. Every number in the example is derived on the page, so you can swap in your own.

MD Integrations sells a 50-state, physician-only clinical network that you plug into your own storefront through an API, a white-label intake layer, or its Shopify and WooCommerce integrations. Turbopills sells the whole stack around the clinicians: storefront, intake, billing, pharmacy routing, portal and app. Which one you need depends mostly on whether you already have engineers and a store. Here is the comparison, built only from public facts.

On a white-label platform, a single-state telehealth brand usually sees its first patient 8 to 13 weeks after incorporation and runs paid ads a few weeks later. A custom build takes 5 to 9 months for the same launch. The difference is almost entirely the software track, because the paperwork (entities, licensure, pharmacy, processor, LegitScript) takes the same time on both paths. Here is the week-by-week timeline for each, and which steps can run at the same time.

We read forty Reddit threads posted between April and September 2026 by people launching, running or abandoning telehealth brands, across r/TeleMedicine, r/telehealth, r/nursepractitioner, r/PMHNP, r/MedSpa, r/PaymentProcessing, r/EntrepreneurRideAlong and the patient subreddits they sell to. Six things go wrong, in the same order, in almost every story. Here they are in the founders' own words, with dates, and an honest note on which of them a platform like ours removes and which it cannot.

A telehealth subscription is not a SaaS subscription with a doctor attached. The charge has to wait for a clinical approval, the cycle has to follow the pharmacy's fill, the price changes with the dose, and the processor treats the whole category as restricted. Stripe Billing (0.7% of volume), Recurly ($249 a month plus 0.9%) and Chargebee (0.8%, or $99 plus 0.65%) are excellent general billers that know none of that. Here is what each costs at 500 patients, where each breaks on telehealth's six special cases, and when a platform-native engine is the right answer.

A $4 million supplement brand went live with a GLP-1 program in five weeks this spring, ran its first cohort profitably with no paid acquisition, and within 90 days the clinical channel out-earned any single supplement product, according to the case study its platform vendor published in May. The mechanism is not complicated: a customer list that already trusts you, a clinical storefront that runs beside Shopify rather than inside its cart, and a program the customer was going to buy from Hims anyway. Here is the architecture, the programs that fit each kind of brand, the data boundary you must not cross, and the five-week plan.

Med spa owners are asking the same question in every Facebook group this fall: who are you using for GFEs and GLP-1 telehealth, and does it actually work without hiring anyone? The honest answer is that 'adding telehealth' means one of three very different things, from a $28 good-faith exam to a prescription program under your own brand, and the right one depends on who owns the medical side of your spa today. Here are the three models, the five compliance questions, the programs that fit a spa, and the workflow that runs between visits without a new hire.

Peptides are the most-searched new clinic category of 2026 and the most misunderstood. FDA moved twelve peptides off its Category 2 list in April, an advisory committee reviewed seven of them in July, Hims says it has six ready to launch, and as of September none of that had made BPC-157 legal to prescribe (HHS's October 28 enforcement policy has since changed that, with conditions). Here is the legal map as of September 2026, the peptides a clinic can actually offer today, the launch stack, what it costs to do it yourself versus on a platform, and the day-one plan for when the FDA list finally moves.

In 2026 the white-label telehealth category split into a flat-fee lane: Remedora at $200 a month, Karpa from $297, Cuvo at $997 or $2,000 plus $25 a consult, and a handful of others with numbers on their pricing pages. We are the fourth name in this comparison and we do not publish a price yet, so we wrote it with the rules from our other comparisons: only public numbers, plain statements about who each platform is for, and the questions to ask each of us before signing.

Yes, a nurse practitioner can start a telehealth weight loss practice, and in the roughly 28 states with full practice authority the NP can own it outright. The work is in the details that Reddit threads argue about at two in the morning: the collaborating physician who costs 'the most painful $700 a month', the state-by-state licensing, malpractice at $2,400 a year, and the choice between insurance that pays thirty cents on the dollar and cash pay that does not. Here is the whole path, with prices.

Is it too late to start a GLP-1 telehealth business? Too late for the 2024 version, where a $99 compounded vial and a Facebook ad account made a company. Not too late for the version that is actually working in the third quarter of 2026: a niche, a retention system, branded drugs the manufacturer ships, and fixed costs low enough that 500 patients is a business. Here is what died, what the numbers say still works, and the three things that now count as a moat.

The fourth quarter of 2026 has more dated decisions stacked into it than any quarter since the shortage ended: a 503B final order that can land any week, a DEA rule sitting at the White House since August 25, a CagriSema decision, a $199 manufacturer promo that expires December 31, and an open-enrollment season in which employers are quietly dropping GLP-1 coverage. Here is every date we know, what is still undated, and the build item that belongs in front of each one.

If you are shopping for an OpenLoop alternative in September 2026, the honest shortlist has nine names across three lanes, and the differences that matter are not features. They are who publishes a price, who holds the merchant account and the patient relationship, and how many weeks pass before your first patient. Here is the table, the questions the January breach added to every vendor call, and where we fit.

LegitScript certification costs $975 to apply and $2,150 a year per website, takes anywhere from two business days on the expedited path to eleven weeks doing it yourself, and gates Meta, Google, Microsoft and TikTok ads for any telehealth brand. Founders on Reddit call the process 'confusing af', and the confusion is mostly about who does the work. Here are the nine standards, the documents, the realistic timelines, the compounded-GLP-1 problem, and what a platform can and cannot do about any of it.

A cash-pay telehealth brand in late 2026 keeps somewhere between $60 and $115 of every $149 membership after clinical, platform, processing and support costs, before marketing. At 100 patients that is a side business, at 500 it is a real company, and at 2,000 it is a company with a support team and a tax problem. Here is the model with every assumption exposed, the public-company numbers it is checked against, and the one cost decision that moves the answer more than price does.